{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:45:54Z","timestamp":1785843954968,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Internal research grant from the Affiliated Hospital of North Sichuan Medical College","award":["2023LC009"],"award-info":[{"award-number":["2023LC009"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-026-12034-z","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:16:22Z","timestamp":1785842182000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Osteopontin Promotes Lung Cancer Growth through NF-\u03baB-Dependent Upregulation of PD-L1 and Suppression of Anti-Tumor Immunity"],"prefix":"10.1007","volume":"53","author":[{"given":"Min","family":"Hou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honglei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"key":"12034_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04093-9","author":"BV Landon","year":"2025","unstructured":"Landon BV, Annapragada AV, Niknafs N, Velculescu VE, Anagnostou V (2025) Liquid biopsies across the cancer care continuum. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-04093-9","journal-title":"Nat Med"},{"key":"12034_CR2","doi-asserted-by":"publisher","first-page":"10488","DOI":"10.21037\/jtd-2025-1254","volume":"17","author":"H Qi","year":"2025","unstructured":"Qi H, Chai X, Zhou F, Jiang Y, Bao Y (2025) A narrative review of the early diagnosis and treatment of idiopathic pulmonary fibrosis with lung cancer. J Thorac Dis 17:10488\u201310500. https:\/\/doi.org\/10.21037\/jtd-2025-1254","journal-title":"J Thorac Dis"},{"key":"12034_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms262311646","author":"N Torounidou","year":"2025","unstructured":"Torounidou N et al (2025) Fatal myocarditis following adjuvant immunotherapy: a case report and literature review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms262311646","journal-title":"Int J Mol Sci"},{"key":"12034_CR4","doi-asserted-by":"publisher","first-page":"218203","DOI":"10.1016\/j.canlet.2025.218203","volume":"639","author":"X Dong","year":"2025","unstructured":"Dong X et al (2025) Strategies to optimize duration of immunotherapy in advanced NSCLC: Current evidence and future directions. Cancer Lett 639:218203. https:\/\/doi.org\/10.1016\/j.canlet.2025.218203","journal-title":"Cancer Lett"},{"key":"12034_CR5","doi-asserted-by":"publisher","first-page":"426","DOI":"10.7150\/ijbs.118831","volume":"22","author":"J Li","year":"2026","unstructured":"Li J, Song N, Ma R, Qu X (2026) Unravelling resistance: integrating metabolism, epigenetics, immunology, and proteostasis in strategies against Kirsten Rat Sarcoma Viral Oncogene Homolog-mutant colorectal cancer. Int J Biol Sci 22:426\u2013446. https:\/\/doi.org\/10.7150\/ijbs.118831","journal-title":"Int J Biol Sci"},{"key":"12034_CR6","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2025.15399","volume":"31","author":"J Ma","year":"2026","unstructured":"Ma J, Jiang J (2026) Exploration of immunotherapy modalities in stage III unresectable non-small cell lung cancer (review). Oncol Lett 31:46. https:\/\/doi.org\/10.3892\/ol.2025.15399","journal-title":"Oncol Lett"},{"key":"12034_CR7","doi-asserted-by":"publisher","first-page":"5137","DOI":"10.21037\/tlcr-2025-886","volume":"14","author":"Q Wang","year":"2025","unstructured":"Wang Q et al (2025) The pathogenesis and therapeutic management of rare pulmonary sarcomatoid carcinoma: a narrative review. Transl Lung Cancer Res 14:5137\u20135158. https:\/\/doi.org\/10.21037\/tlcr-2025-886","journal-title":"Transl Lung Cancer Res"},{"key":"12034_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26199307","author":"J Piekarz","year":"2025","unstructured":"Piekarz J, Picheta N, Szklener K, Ma\u0144dziuk S (2025) TIGIT expression and its implications in non-small-cell lung cancer progression and therapy: a systematic review. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms26199307","journal-title":"Int J Mol Sci"},{"key":"12034_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1691980","volume":"16","author":"X Shi","year":"2025","unstructured":"Shi X et al (2025) Overcoming resistance to immune checkpoint inhibitor in non-small cell lung cancer: the promise of combination therapy. Front Immunol 16:1691980. https:\/\/doi.org\/10.3389\/fimmu.2025.1691980","journal-title":"Front Immunol"},{"key":"12034_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-025-01927-1","volume":"26","author":"L Wang","year":"2025","unstructured":"Wang L, Xian X, Ke H, Wang K (2025) Immunotherapy in EGFR-mutant non-small cell lung cancer. Clin Exp Med 26:10. https:\/\/doi.org\/10.1007\/s10238-025-01927-1","journal-title":"Clin Exp Med"},{"key":"12034_CR11","doi-asserted-by":"publisher","first-page":"9193","DOI":"10.1097\/ms9.0000000000004256","volume":"87","author":"M Abid","year":"2025","unstructured":"Abid M, Abu Nahla U, Saddique MN (2025) Tumor-localized immunomodulation: a critical advance in engineering CAR-t cells for solid malignancies. Ann Med Surg (Lond) 87:9193\u20139194. https:\/\/doi.org\/10.1097\/ms9.0000000000004256","journal-title":"Ann Med Surg (Lond)"},{"key":"12034_CR12","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2025.2595788","volume":"14","author":"I Rastogi","year":"2025","unstructured":"Rastogi I, McNeel DG (2025) Prostate tumor immune microenvironment changes following immunotherapy shared by patients who developed anti-tumor response or immune-related adverse events. Oncoimmunology 2595788. https:\/\/doi.org\/10.1080\/2162402x.2025.2595788","journal-title":"Oncoimmunology"},{"key":"12034_CR13","doi-asserted-by":"publisher","first-page":"10445","DOI":"10.21037\/jtd-2025-1945","volume":"17","author":"QX Zheng","year":"2025","unstructured":"Zheng QX et al (2025) Pseudomonas putida KT2440-induced RBM47 regulates non-small cell lung cancer stem cell properties and T cell-mediated antitumor activity. J Thorac Dis 10445\u201310458. https:\/\/doi.org\/10.21037\/jtd-2025-1945","journal-title":"J Thorac Dis"},{"key":"12034_CR14","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1080\/1744666x.2025.2585347","volume":"21","author":"X Lv","year":"2025","unstructured":"Lv X, Tan X, Xiao Z, Chen W, Xu Y (2025) TCF3 activates VEGFA transcription and reinforces PD-L1 expression in lung adenocarcinoma cells via NF-\u03baB to attenuate the cytotoxicity of CD8(+) T cells. Expert Rev Clin Immunol 21:1685\u20131698. https:\/\/doi.org\/10.1080\/1744666x.2025.2585347","journal-title":"Expert Rev Clin Immunol"},{"key":"12034_CR15","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13062-025-00704-0","volume":"20","author":"X Quan","year":"2025","unstructured":"Quan X, Li N, Huang J, Duan Y (2025) CLOCK-mediated acetylation of NF-\u03baB p65 drives immune evasion in breast cancer. Biol Direct 20:112. https:\/\/doi.org\/10.1186\/s13062-025-00704-0","journal-title":"Biol Direct"},{"key":"12034_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17132245","author":"CI Aquino","year":"2025","unstructured":"Aquino CI et al (2025) Osteopontin expression and its role in endometrial cancer: a systematic review. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers17132245","journal-title":"Cancers (Basel)"},{"key":"12034_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgaf034","author":"CF Chou","year":"2025","unstructured":"Chou CF et al (2025) Constitutive epidermal expression of osteopontin in osteopontin-null mice restores ultraviolet B-induced cutaneous squamous cell carcinomas to wild-type levels. Carcinogenesis. https:\/\/doi.org\/10.1093\/carcin\/bgaf034","journal-title":"Carcinogenesis"},{"key":"12034_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/s25123628","author":"A Sankiewicz","year":"2025","unstructured":"Sankiewicz A, \u017belazowska-Rutkowska B, Guszcz T, Gorodkiewicz E (2025) Development of an SPRi immune method for the quantitative detection of osteopontin. Sensors (Basel). https:\/\/doi.org\/10.3390\/s25123628","journal-title":"Sensors (Basel)"},{"key":"12034_CR19","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.7150\/thno.113347","volume":"16","author":"RK Kim","year":"2026","unstructured":"Kim RK et al (2026) A novel TM4SF4-targeting therapeutic antibody candidate with antitumor activity by blocking IGF1R and CD44 signaling and downregulating PD-L1 and B7-H4. Theranostics 1762\u20131781. https:\/\/doi.org\/10.7150\/thno.113347","journal-title":"Theranostics"},{"key":"12034_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1435-2","volume":"10","author":"R Zhang","year":"2019","unstructured":"Zhang R et al (2019) Cancer-associated fibroblasts enhance tumor-associated macrophages enrichment and suppress NK cells function in colorectal cancer. Cell Death Dis 273. https:\/\/doi.org\/10.1038\/s41419-019-1435-2","journal-title":"Cell Death Dis"},{"key":"12034_CR21","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.immuni.2024.02.007","volume":"57","author":"A Franken","year":"2024","unstructured":"Franken A et al (2024) CD4(+) T cell activation distinguishes response to anti-PD-L1\u2009+\u2009anti-CTLA4 therapy from anti-PD-L1 monotherapy. Immunity 57:541-558.e547. https:\/\/doi.org\/10.1016\/j.immuni.2024.02.007","journal-title":"Immunity"},{"key":"12034_CR22","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jhep.2023.02.032","volume":"79","author":"J Tan","year":"2023","unstructured":"Tan J et al (2023) TREM2(+) macrophages suppress CD8(+) T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma. J Hepatol 79:126\u2013140. https:\/\/doi.org\/10.1016\/j.jhep.2023.02.032","journal-title":"J Hepatol"},{"key":"12034_CR23","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ccell.2024.11.008","volume":"43","author":"Z Yang","year":"2025","unstructured":"Yang Z et al (2025) Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1. Cancer Cell 43:86-102.e110. https:\/\/doi.org\/10.1016\/j.ccell.2024.11.008","journal-title":"Cancer Cell"},{"key":"12034_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53023-9","volume":"15","author":"Y Gu","year":"2024","unstructured":"Gu Y et al (2024) Osteopontin is a therapeutic target that drives breast cancer recurrence. Nat Commun 15:9174. https:\/\/doi.org\/10.1038\/s41467-024-53023-9","journal-title":"Nat Commun"},{"key":"12034_CR25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113379","author":"HR Moorman","year":"2020","unstructured":"Moorman HR et al (2020) Osteopontin: a key regulator of tumor progression and immunomodulation. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers12113379","journal-title":"Cancers (Basel)"},{"key":"12034_CR26","doi-asserted-by":"publisher","first-page":"169","DOI":"10.31083\/j.jin2309169","volume":"23","author":"P Li","year":"2024","unstructured":"Li P, Tao Z, Zhao X (2024) The Role of Osteopontin (OPN) in Regulating Microglia Phagocytosis in Nervous System Diseases. J Integr Neurosci 23:169. https:\/\/doi.org\/10.31083\/j.jin2309169","journal-title":"J Integr Neurosci"},{"key":"12034_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/intimm\/dxac060","volume":"35","author":"EY Lin","year":"2023","unstructured":"Lin EY, Xi W, Aggarwal N, Shinohara ML (2023) Osteopontin (OPN)\/SPP1: from its biochemistry to biological functions in the innate immune system and the central nervous system (CNS). Int Immunol 35:171\u2013180. https:\/\/doi.org\/10.1093\/intimm\/dxac060","journal-title":"Int Immunol"},{"key":"12034_CR28","doi-asserted-by":"publisher","first-page":"1285951","DOI":"10.3389\/fimmu.2023.1285951","volume":"14","author":"S Tang","year":"2023","unstructured":"Tang S et al (2023) OPN promotes pro-inflammatory cytokine expression via ERK\/JNK pathway and M1 macrophage polarization in Rosacea. Front Immunol 14:1285951. https:\/\/doi.org\/10.3389\/fimmu.2023.1285951","journal-title":"Front Immunol"},{"key":"12034_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.919366","volume":"13","author":"RJ Bai","year":"2022","unstructured":"Bai RJ et al (2022) OPN inhibits autophagy through CD44, integrin and the MAPK pathway in osteoarthritic chondrocytes. Front Endocrinol (Lausanne) 13:919366. https:\/\/doi.org\/10.3389\/fendo.2022.919366","journal-title":"Front Endocrinol (Lausanne)"},{"key":"12034_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-01009-7","volume":"13","author":"Y Fu","year":"2020","unstructured":"Fu Y et al (2020) Abnormally activated OPN\/integrin \u03b1V\u03b23\/FAK signalling is responsible for EGFR-TKI resistance in EGFR mutant non-small-cell lung cancer. J Hematol Oncol 13:169. https:\/\/doi.org\/10.1186\/s13045-020-01009-7","journal-title":"J Hematol Oncol"},{"key":"12034_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/jev2.12203","volume":"11","author":"S Chen","year":"2022","unstructured":"Chen S et al (2022) \u03b2-catenin-controlled tubular cell-derived exosomes play a key role in fibroblast activation via the OPN-CD44 axis. J Extracell Vesicles 11:e12203. https:\/\/doi.org\/10.1002\/jev2.12203","journal-title":"J Extracell Vesicles"},{"key":"12034_CR32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.gendis.2020.06.006","volume":"9","author":"Q Liu","year":"2022","unstructured":"Liu Q et al (2022) Osteopontin inhibits osteoarthritis progression via the OPN\/CD44\/PI3K signal axis. Genes Dis 9:128\u2013139. https:\/\/doi.org\/10.1016\/j.gendis.2020.06.006","journal-title":"Genes Dis"},{"key":"12034_CR33","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571. https:\/\/doi.org\/10.1038\/nature13954","journal-title":"Nature"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12034-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-026-12034-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-026-12034-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:16:23Z","timestamp":1785842183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-026-12034-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["12034"],"URL":"https:\/\/doi.org\/10.1007\/s11033-026-12034-z","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"7 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experimental procedures were reviewed and approved by the Animal Ethics Committee of the Affiliated Hospital of North Sichuan Medical College.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Clinical trial number: not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1344"}}